B cell lymphoma is a cancer of the white blood cells, which develops when the body starts making abnormal B cells. Abnormal B cells hinder the body’s ability to fight infection and weaken the immune system. Current treatment options for B cell lymphoma, which include chimeric antigen receptor (CAR) T cells are too toxic and do not kill cancer cells in a solid tumor. Therefore, CAR macrophages, which are known to target solid tumors may result in a cancer treatment option that targets and kills cells in solid tumors, while leaving the normal cells unaffected. The ability to produce CAR macrophages will lead to a large advancement in treatment options for solid tumors.